HK1078095A1 - Corticotropin releasing factor receptor 2 agonists - Google Patents

Corticotropin releasing factor receptor 2 agonists

Info

Publication number
HK1078095A1
HK1078095A1 HK05110114A HK05110114A HK1078095A1 HK 1078095 A1 HK1078095 A1 HK 1078095A1 HK 05110114 A HK05110114 A HK 05110114A HK 05110114 A HK05110114 A HK 05110114A HK 1078095 A1 HK1078095 A1 HK 1078095A1
Authority
HK
Hong Kong
Prior art keywords
agonists
factor receptor
releasing factor
corticotropin releasing
corticotropin
Prior art date
Application number
HK05110114A
Other languages
English (en)
Inventor
Robert Joseph Isfort
Wieslaw Adam Mazur
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of HK1078095A1 publication Critical patent/HK1078095A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57509Corticotropin releasing factor [CRF] (Urotensin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK05110114A 2002-01-16 2005-11-11 Corticotropin releasing factor receptor 2 agonists HK1078095A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34911702P 2002-01-16 2002-01-16
US37633702P 2002-04-29 2002-04-29
US38889502P 2002-06-14 2002-06-14
US41198802P 2002-09-19 2002-09-19
PCT/US2003/001454 WO2003062277A1 (en) 2002-01-16 2003-01-16 Corticotropin releasing factor receptor 2 agonists

Publications (1)

Publication Number Publication Date
HK1078095A1 true HK1078095A1 (en) 2006-03-03

Family

ID=27617822

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05110114A HK1078095A1 (en) 2002-01-16 2005-11-11 Corticotropin releasing factor receptor 2 agonists

Country Status (30)

Country Link
US (7) US6936585B2 (de)
EP (4) EP1465922B1 (de)
JP (3) JP4508648B2 (de)
KR (3) KR100735586B1 (de)
CN (3) CN100475844C (de)
AR (3) AR038143A1 (de)
AT (4) ATE398632T1 (de)
AU (2) AU2003205197B2 (de)
BR (3) BR0306838A (de)
CA (3) CA2470731C (de)
CY (1) CY1106133T1 (de)
DE (4) DE60321730D1 (de)
DK (2) DK1465921T3 (de)
ES (4) ES2299701T3 (de)
HK (1) HK1078095A1 (de)
IL (5) IL162530A0 (de)
MA (3) MA27592A1 (de)
MX (3) MXPA04006884A (de)
MY (1) MY140306A (de)
NO (3) NO20043366L (de)
NZ (3) NZ533598A (de)
PE (3) PE20030849A1 (de)
PL (3) PL371364A1 (de)
PT (2) PT1465921E (de)
RU (1) RU2294333C2 (de)
SA (3) SA03230565B1 (de)
SI (1) SI1465921T1 (de)
TW (3) TWI300442B (de)
WO (3) WO2003062277A1 (de)
ZA (1) ZA200404995B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2427490A1 (en) * 2000-09-22 2002-03-28 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr)
US6936585B2 (en) * 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2005103690A2 (en) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)
EP1871888A4 (de) * 2005-03-30 2013-08-21 Novartis Vaccines & Diagnostic Haemophilus-influenzae vom typ b
WO2007090087A2 (en) * 2006-01-27 2007-08-09 Research Development Foundation Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases
US20100216722A1 (en) * 2007-09-11 2010-08-26 Dorian Bevec Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent
RU2010114038A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение адреномедуллина в качестве терапевтического средства для лечения избыточного ангиогенеза
WO2009046874A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic combination of trh-potentiating peptide and stresscopin
AU2009313619A1 (en) 2008-11-04 2010-05-14 Janssen Pharmaceutica Nv CRHR2 peptide agonists and uses thereof
EP2206726A1 (de) * 2009-01-08 2010-07-14 Universite Joseph Fourier Nichtinvasive Instrumente zum Nachweisen anfälliger atherosklerotischer Plaques
AU2010315131A1 (en) * 2009-11-04 2012-05-31 Janssen Pharmaceutica Nv Method for treating heart failure with stresscopin-like peptides
US9314506B2 (en) 2011-10-24 2016-04-19 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
HUE036640T2 (hu) * 2012-02-14 2018-07-30 Univ California Parakrin gének szisztémás bejuttatása és szabályozott expressziója szív és érrendszeri betegségekre és egyéb állapotokra
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
CA3040889A1 (en) * 2016-10-20 2018-04-26 Cortene Inc. Methods of treating diseases resulting from a maladapted stress response
CN110755434B (zh) * 2018-07-27 2022-03-15 中国医学科学院药物研究所 化合物palosuran防治骨骼肌萎缩等疾病的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235036A (en) * 1991-05-31 1993-08-10 The Salk Institute For Biological Studies Crf analogs
EP0860501A3 (de) 1994-06-14 1999-05-19 Neurocrine Biosciences, Inc. Corticotropin freisetzende Rezeptoren des Faktor 2
US5786203A (en) * 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5663292A (en) * 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5824771A (en) * 1994-12-12 1998-10-20 The Salk Institute For Biological Studies Cyclic CRF agonists
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
WO1997000063A2 (en) 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Urocortin peptides
US5869450A (en) * 1996-03-06 1999-02-09 The Regents Of The University Of California Anti-inflammatory compositions and method with corticotropin-releasing factor analogs
EP1305334B1 (de) 2000-08-04 2008-09-17 Research Development Foundation Urocortinproteine und deren verwendungen
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US6936585B2 (en) 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists

Also Published As

Publication number Publication date
US7632933B2 (en) 2009-12-15
CA2470743A1 (en) 2003-07-31
EP1724283A3 (de) 2007-04-11
DE60313845D1 (de) 2007-06-28
WO2003062268A3 (en) 2003-11-27
US20100197579A1 (en) 2010-08-05
US20060025339A1 (en) 2006-02-02
CA2470731A1 (en) 2003-07-31
PE20030974A1 (es) 2003-12-26
IL162530A0 (en) 2005-11-20
JP4508649B2 (ja) 2010-07-21
JP2005525101A (ja) 2005-08-25
SA03230564B1 (ar) 2006-10-31
KR100758858B1 (ko) 2007-09-14
DK1465921T3 (da) 2006-11-27
NZ533600A (en) 2007-02-23
ES2269976T3 (es) 2007-04-01
EP1465922A2 (de) 2004-10-13
MA27592A1 (fr) 2005-11-01
BR0306826A (pt) 2005-09-06
IL197774A0 (en) 2009-12-24
US20030148956A1 (en) 2003-08-07
EP1465921A2 (de) 2004-10-13
US20090124793A1 (en) 2009-05-14
US20030148958A1 (en) 2003-08-07
SA03230565B1 (ar) 2006-10-31
CY1106133T1 (el) 2011-06-08
KR20040082392A (ko) 2004-09-24
ATE362488T1 (de) 2007-06-15
NO20043366L (no) 2004-10-06
AR038143A1 (es) 2004-12-29
BR0306878A (pt) 2004-10-26
US7192924B2 (en) 2007-03-20
CA2470731C (en) 2011-06-21
PL371364A1 (en) 2005-06-13
PL373529A1 (en) 2005-09-05
BR0306838A (pt) 2005-04-05
AU2003205197B2 (en) 2006-03-02
CA2470743C (en) 2011-12-13
ATE398632T1 (de) 2008-07-15
EP1465923B1 (de) 2007-05-16
IL162431A0 (en) 2005-11-20
NZ533598A (en) 2007-03-30
WO2003062269A3 (en) 2003-11-06
PL373139A1 (en) 2005-08-22
US7462597B2 (en) 2008-12-09
ES2309909T3 (es) 2008-12-16
KR20040082389A (ko) 2004-09-24
PT1465921E (pt) 2006-12-29
CN100391972C (zh) 2008-06-04
JP4508648B2 (ja) 2010-07-21
US7897731B2 (en) 2011-03-01
US20030148957A1 (en) 2003-08-07
SA03230565A (ar) 2005-12-03
JP2005522191A (ja) 2005-07-28
CN1617887A (zh) 2005-05-18
WO2003062277A1 (en) 2003-07-31
CN100475844C (zh) 2009-04-08
EP1724283A2 (de) 2006-11-22
WO2003062268A2 (en) 2003-07-31
IL162529A0 (en) 2005-11-20
NO20043396L (no) 2004-10-06
MXPA04006884A (es) 2004-12-06
MXPA04006883A (es) 2004-12-06
CA2470656C (en) 2011-06-28
RU2004124847A (ru) 2005-04-20
EP1465921B1 (de) 2006-07-26
US7608701B2 (en) 2009-10-27
SA03230564A (ar) 2005-12-03
CN1617886A (zh) 2005-05-18
DE60307044T2 (de) 2007-02-15
PE20030849A1 (es) 2003-12-01
ATE383372T1 (de) 2008-01-15
DE60318547D1 (de) 2008-02-21
US6936585B2 (en) 2005-08-30
ES2299701T3 (es) 2008-06-01
KR100758857B1 (ko) 2007-09-14
MA27591A1 (fr) 2005-11-01
ZA200404995B (en) 2005-06-29
AR038142A1 (es) 2004-12-29
RU2294333C2 (ru) 2007-02-27
EP1724283B1 (de) 2008-06-18
CA2470656A1 (en) 2003-07-31
NO20043371L (no) 2004-10-06
AU2003237419B2 (en) 2006-04-13
MA27590A1 (fr) 2005-11-01
EP1465922B1 (de) 2008-01-09
EP1465923A1 (de) 2004-10-13
US7192923B2 (en) 2007-03-20
TW200302277A (en) 2003-08-01
DE60313845T2 (de) 2008-01-31
PT1465923E (pt) 2007-08-06
KR100735586B1 (ko) 2007-07-04
MXPA04006885A (es) 2004-12-06
ATE334147T1 (de) 2006-08-15
JP4489434B2 (ja) 2010-06-23
TW200302276A (en) 2003-08-01
KR20040082390A (ko) 2004-09-24
DE60321730D1 (de) 2008-07-31
ES2287484T3 (es) 2007-12-16
AR038144A1 (es) 2004-12-29
US20080004435A1 (en) 2008-01-03
IL196384A0 (en) 2011-07-31
PE20030747A1 (es) 2003-10-23
DE60318547T2 (de) 2008-12-24
SI1465921T1 (sl) 2006-10-31
TWI300442B (en) 2008-09-01
WO2003062269A2 (en) 2003-07-31
TW200302278A (en) 2003-08-01
NZ533599A (en) 2007-03-30
DE60307044D1 (de) 2006-09-07
MY140306A (en) 2009-12-31
CN1617885A (zh) 2005-05-18
DK1465923T3 (da) 2007-07-02
JP2005521387A (ja) 2005-07-21

Similar Documents

Publication Publication Date Title
IL196384A0 (en) Corticotropin releasing factor 2 receptor agonists
EP1482895A4 (de) Aminoalkylphosphonate und verwandte verbindungen als edg-rezeptoragonisten
AP1916A (en) Purine compounds and use thereof as cannabinoid receptor ligands
IL150632A0 (en) Corticotropin releasing factor antagonists
EP1482896A4 (de) Aminoalkylphosphonate und verwandte verbindungen als edg-rezeptor-agonisten
EP1559422A4 (de) Mittel zur kontrolle der rezeptorfunktion
HUP0401437A3 (en) Adenosine a3 receptor agonists
AU6497701A (en) Melanocortin receptor agonists
AU2003236205A1 (en) Glucagon antagonists/inverse agonists
AU2002351730A1 (en) Glucagon receptor antagonists/inverse agonists
AU2003248356A1 (en) Beta3-adrenergic receptor agonists
GB0226227D0 (en) Receptors
ZA200404994B (en) Corticotropin releasing factor 2 receptor agonists
SI1465923T1 (sl) Agonisti receptorja 2 faktorja sproščanja kortikotropina
GB0215389D0 (en) Receptor
AU2003300867A8 (en) Uses of the snorf207 receptor
GB0223399D0 (en) Receptors
AU2002302807A1 (en) Corticotropin releasing factor antagonists
GB0201849D0 (en) A�- adenosine receptor agonists
SI1558615T1 (sl) Purinske spojine in uporaba le-teh kot ligandov kanabinoidnega receptorja
GB0408454D0 (en) Leptin receptor agonists (1)
GB0408398D0 (en) Leptin receptor agonists (3)
GB0302925D0 (en) 4P re use 001
AU2003297644A8 (en) Uses of the snorf55 receptor
GB0228112D0 (en) Receptors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130116